3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Squamous Intraepithelial Lesions
1
Skin Neoplasms
1
Precancerous Conditions
1
Papillomavirus Infections
1
Papilloma
1
Lung Neoplasms
1
Laryngeal papillomatosis
1
Keratosis, Actinic
1
Hyperthermia
1
HIV Infections
1
Cicatrix
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Anus Neoplasms
1
Acquired Immunodeficiency Syndrome
1
Interventions
human papillomavirus vaccine, L1 type 16, 18
30
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
20
Papillomavirus Vaccines
9
Radiotherapy, Intensity-Modulated
4
Cisplatin
4
Blood Specimen Collection
4
fludarabine
3
Vaccines, Synthetic
3
Engerix-B
3
Cyclophosphamide
3
halofantrine
2
fludarabine phosphate
2
aldesleukin
2
Watchful Waiting
2
Vaccines
2
Patient Navigation
2
Paclitaxel
2
Light Coagulation
2
Interleukin-2
2
Imiquimod
2
Human Papillomavirus Recombinant Vaccine nonavalent
2
Hepatitis A Vaccines
2
Fluorouracil
2
Electrocoagulation
2
Cetuximab
2
Carboplatin
2
Albumin-Bound Paclitaxel
2
utomilumab
1
polyphenon E
1
infigratinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Papillomavirus Infections
×
Laser Therapy
×
Clear all
NCT02135419
2024-07-26
ANCHOR
AIDS Malignancy Consortium
Phase 3
Completed
4,446 enrolled
13 charts